Oppenheimer Assumes Ionis Pharmaceuticals (IONS) at Outperform

Oppenheimer analyst Justin Kim assumes coverage on Ionis Pharmaceuticals (NASDAQ: IONS) with a Outperform rating and a price target of $59.00.

For an analyst ratings summary and ratings history on Ionis Pharmaceuticals click here. For more ratings news on Ionis Pharmaceuticals click here.

Shares of Ionis Pharmaceuticals closed at $39.31 yesterday.

You May Also Be Interested In

• Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
• Oppenheimer Starts Carriage Services (CSV) at Outperform
• Evercore ISI Starts Alvotech SA (ALVO) at Outperform